AnjiPharmaUS is a biopharmaceutical company dedicated to improving lives globally. They prioritize asset-centric drug development to deliver accessible medicines to millions of patients. By selecting targets with strong human evidence and a clear path to value, Anji maximizes the potential of each asset.

Their comprehensive and capital-efficient clinical development programs unlock value through clinical proof-of-concept, ensuring a well-diversified and renewable product pipeline. AnjiPharmaUS is currently focused on two significant therapeutic areas. ANJ900, a metformin-based therapy, is in Phase 3 pivotal trials to treat type 2 diabetes patients with chronic kidney disease.

ANJ908 is a groundbreaking novel mechanism to address chronic constipation, validated in humans. The company has completed a multinational Phase 2 proof-of-concept study for ANJ908. Inspired by the historic Anji Bridge, known for safe crossing and aiding those in need, AnjiPharmaUS builds bridges between science and cultures to create safe and effective medicines.

Their experienced team combines profound drug development expertise with a determination to make a difference. For patients, they offer resources to navigate chronic constipation and type 2 diabetes with chronic kidney disease. Partnership opportunities and further information can be obtained by contacting them directly